ALDX - Aldeyra Therapeutics, Inc.
8.14 0.00 (0.00%)
After hours: 4:34PM EDT
| Previous Close | 8.10 |
| Open | 8.08 |
| Bid | 7.20 x 1800 |
| Ask | 8.25 x 1100 |
| Day's Range | 8.00 - 8.26 |
| 52 Week Range | 6.75 - 16.70 |
| Volume | 192,139 |
| Avg. Volume | 678,569 |
| Market Cap | 222.999M |
| Beta (3Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.79 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.88 |
- PR Newswire•16 days ago
Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Reproxalap is a novel immune-modulating RASP (Reactive Aldehyde Species) inhibitor in late-stage development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Results from a Phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. The RENEW adaptive Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease initiated on April 1, 2019.
- PR Newswire•23 days ago
Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the RENEW Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease. The RENEW Trial is a two-part, multi-center, randomized, double-masked, parallel-group, vehicle-controlled, adaptive Phase 3 clinical trial evaluating the efficacy of reproxalap ophthalmic solution (0.25%) vs. vehicle in 400 patients with moderate-to-severe dry eye disease. Results from the first part of the trial will confirm the dosing regimen and sample size for the second part. The co-primary endpoints of the trial will be ocular dryness and fluorescein nasal region ocular staining in pre-specified moderate to severe patient subsets analyzed over twelve weeks of therapy using Mixed effects Model Repeated Measures (MMRM).
- Zacks•29 days ago
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
- TheStreet.com•29 days ago
Future Brightens for 2 Small Biotech Stocks
The biotech sector got off to a quick start in 2019 but largely has been range-bound here in March -- not that things have not been exciting. Small-cap concerns in the sector also have become more volatile in the last few trading sessions.
- Motley Fool•last month
Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
The small-cap pharma announced positive results from a phase 3 trial.
- American City Business Journals•last month
Aldeyra stock jumps 50 percent after eye allergy trial success
Quiet local biotech Aldeyra Therapeutics made some noise Tuesday, reporting that its first treatment for eye allergies succeeded in a late-stage trial.
- Reuters•last month
Aldeyra's eye drug meets main goal in late-stage study, shares surge
The study tested two doses of the drug in 318 patients with seasonal allergic conjunctivitis, an allergic reaction to substances such as pollen or spores causing eye inflammation. Both concentrations of reproxalap exhibited an anti-inflammatory profile distinct from standard-of-care and support a different mechanism of action for the treatment of allergic conjunctivitis, the company said. The results suggest the potential of reproxalap being used to complement existing therapy, Aldeyra Chief Medical Officer David Clark said in a statement.
- Simply Wall St.•last month
Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It's been a soft week for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Read More...
- MarketWatch•last month
Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints
Shares of Aldeyra Therapeutics Inc. shot up 56% toward a 5-month high in premarket trade Tuesday, a day after closing at a 7-month low, after a phase 3 trial of the biotechnology company's allergic conjunctivitis treatment met its primary and secondary endpoints. Trading volume topped 440,000 shares, already more than the full-day average of about 310,000 shares. Aldeyra said it plans to meet with regulatory authorities in the second half of 2019 to discuss the results and remaining clinical requirements for potential submission of a new drug application (NDA) to the Food and Drug Administration. Separately, the company said it entered into a loan and security agreement with Hercules Capital Inc. that provides up to $60 million in financing. "The ALLEVIATE [trial] results suggest the potential of topical ocular reproxalap as a novel, safe, and effective therapeutic option that could be used to complement existing therapy before resorting to corticosteroids, which can lead to serious ocular toxicity," said Aldeyra Chief Medical Officer David Clark. The stock has lost 14.5% over the past 12 months while the iShares Nasdaq Biotechnology ETF has edged up 0.2% and the S&P 500 has gained 5.3%.
- PR Newswire•last month
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap. "We are thrilled to announce positive results from ALLEVIATE, our first completed Phase 3 clinical trial," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.
- PR Newswire•last month
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
LEXINGTON, Mass. , March 25, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...
- Zacks•last month
Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
Aldeyra (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT
Q4 2018 Aldeyra Therapeutics Inc Earnings Call
Motley Fool•2 months agoAldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript
ALDX earnings call for the period ending December 31, 2018.
- PR Newswire•2 months ago
Aldeyra Therapeutics Announces Year-End 2018 Financial Results
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 - The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Disease Expected to Begin in First Half of 2019 ...
- PR Newswire•2 months ago
Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
LEXINGTON, Mass. , March 1, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...
- PR Newswire•2 months ago
Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
LEXINGTON, Mass., Feb. 28, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, M.D., the Stelios Evangelos Gragoudas Professor of Ophthalmology at Harvard Medical School, Director of the Retina Service at Massachusetts Eye and Ear Infirmary, and Director of the Retina Fellowship at Harvard and Massachusetts Eye and Ear Infirmary.
- PR Newswire•2 months ago
Aldeyra Therapeutics to Host 2019 Research & Development Day
LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...
- GlobeNewswire•3 months ago
Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
LEXINGTON, Mass., Jan. 29, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company. The acquisition adds to Aldeyra's pipeline a Phase 3-ready product candidate (ADX-2191, intravitreal methotrexate) for the treatment of proliferative vitreoretinopathy (PVR), a serious sight-threatening condition with no approved treatment.
- PR Newswire•3 months ago
Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
LEXINGTON, Mass., Jan. 15, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to inventing, developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Stephen G. Machatha, Ph.D. has been promoted to the position of Senior Vice President, Technical Operations, effective immediately. In his new role, Dr. Machatha will lead Chemistry, Manufacturing and Control activities, and develop Aldeyra's commercial supply infrastructure. Dr. Machatha joined Aldeyra in 2016 as Vice President of Chemistry Manufacturing and Controls.
- PR Newswire•4 months ago
Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer
LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to the position of Chief Commercial Officer, effective immediately. Mr. McMullin joined Aldeyra in May 2018 as Senior Vice President and Head of Corporate Development and Strategy, and has more than 20 years of experience leading commercialization, business development, and strategic planning operations in the biopharmaceutical industry. Prior to joining Aldeyra, Mr. McMullin was Group Vice President and Head of U.S. Internal Medicine at Shire plc, a $1.4 billion commercial business unit. Mr. McMullin also ran Global Commercial Operations at Shire Plc and was an in-line Committee member, responsible for commercial performance and execution worldwide. Prior to his work at Shire, Mr. McMullin held roles of increasing responsibility in corporate strategy, marketing, sales, and operations at Novartis International AG.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT
Q3 2018 Aldeyra Therapeutics Inc Earnings Call
- PR Newswire•4 months ago
Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial
LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed dosing in the ALLEVIATE Phase 3 clinical trial of topical ocular reproxalap in patients with allergic conjunctivitis. "We look forward to announcing the results of the ALLEVIATE clinical trial in early 2019 as the first of three Phase 3 readouts expected next year," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Affecting approximately 20% of the population worldwide, allergic conjunctivitis is a common disease that can cause persistently disturbing symptoms, and is often associated with dry eye disease.
